| Pharmaceutical Information |
| Drug Name |
Romiplostim |
| Drug ID |
BADD_D01965 |
| Description |
Romiplostim is a thrombopoiesis stimulating dimer Fc-peptide fusion protein (peptibody) to increase platelet production through activation of the thrombopoietin receptor. The peptibody molecule has two identical single-chain subunits, each one is made up of 269 amino acid residues. Each subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl. Each domain consists of 14 amino acids. Interestingly, romiplostim's amino acid sequence is not similar to that of endogenous thrombopoietin. Romiplostim is produced by recombinant DNA technology in Escherichia coli. FDA approved on August 22, 2008. |
| Indications and Usage |
Treatment of chronic immune thrombocytopenic purpura. |
| Marketing Status |
approved |
| ATC Code |
B02BX04 |
| DrugBank ID |
DB05332
|
| KEGG ID |
D08990
|
| MeSH ID |
C488777
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
55513-221; 55513-222; 55513-223; 68225-049; 68225-104; 68225-050 |
| UNII |
GN5XU2DXKV
|
| Synonyms |
romiplostim | AMG531 | Amgen Megakaryopoiesis protein 531 | Nplate |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
267639-76-9 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
